Celiprolol--review of airways studies.
Celiprolol was compared with chlorthalidone in a double-blind randomized placebo-controlled study of 30 hypertensive or anginal patients with reversible bronchial obstruction. The study consisted of a 4-week placebo run-in period and a 12-week titration period during which the dose of both drugs was increased at 4-week intervals if blood pressure was not reduced adequately. The doses of celiprolol were 200, 400 or 600 mg once daily, whereas those for chlorthalidone were 12.5, 25 or 37.5 mg once daily. Entry criteria were a diastolic blood pressure between 90 to 115 mm Hg, forced expiratory volume in 1 second between 40 and 80% of predicted value, increasing by 15% or more after salbutamol inhalation and the need for occasional bronchodilator therapy. Prophylactic medication for asthma was given at a constant dosage for 1 month before the study and throughout the study. Clinical variables were not significantly changed by either drug, and neither celiprolol nor chlorthalidone had any significant effect on forced expiratory volume in 1 second.
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications / Q000503:physiopathology; D017272:Celiprolol; D002752:Chlorthalidone / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005541:Forced Expiratory Volume; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D008448:Maximal Expiratory Flow Rate; D011412:Propanolamines / Q000627:therapeutic use*; D012123:Pulmonary Ventilation / Q000187:drug effects*; D011897:Random Allocation; D014797:Vital Capacity
D000959:Antihypertensive Agents; D011412:Propanolamines; D017272:Celiprolol; D002752:Chlorthalidone